Shares of Unity Biotechnology, Inc. (UBX) are experiencing a 9% increase in pre-market trading following the announcement of Federico Grossi's appointment as Chief Medical Officer. Federico Grossi expressed his enthusiasm about advancing UBX1325 and expanding the pipeline to offer new, distinctive treatment options for individuals with progressive retinal diseases. With two decades of experience and extensive expertise in ophthalmology, Grossi is well-equipped for this role. He previously held the position of Chief Medical Officer at Apellis Pharmaceuticals.
On Friday, UBX saw a 12.28% increase, closing at $1.28 on the Nasdaq. In pre-market trading, the company's value has risen an additional 8.59%, reaching $1.39.
